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Although distinct human induced pluripotent stem
cell (hiPSC) lines can display considerable epigenetic
variation, it has been unclear whether such variability
impacts their utility for disease modeling. Here, we
show that although low-passage female hiPSCs
retain the inactive X chromosome of the somatic
cell they are derived from, over time in culture they
undergo an ‘‘erosion’’ of X chromosome inactivation
(XCI). This erosion of XCI is characterized by loss of
XIST expression and foci of H3-K27-trimethylation,
as well as transcriptional derepression of genes on
the inactive X that cannot be reversed by either differ-
entiation or further reprogramming. We specifically
demonstrate that erosion of XCI has a significant
impact on the use of female hiPSCs for modeling
Lesch-Nyhan syndrome. However, our finding that
most genes subject to XCI are derepressed by this
erosion of XCI suggests that it should be a significant
consideration when selecting hiPSC lines for
modeling any disease.
INTRODUCTION
There is considerable interest in the use of human induced
pluripotent stem cells (hiPSCs) for the study of X-linked
diseases, in particular for the understanding of cellular pro-
cesses that lead to X-linked mental retardation and autism
spectrum disorders (Chiurazzi et al., 2008; Marchetto et al.,
2010). However, it remains to be settled how X chromosome
inactivation (XCI) is regulated during reprogramming and during
the long-term culture of female hiPSC lines. Thus, it is difficult
to interpret phenotypes in female hiPSC lines that are caused
by X-linked mutations. For instance, it has been suggested
that hiPSC lines derived from girls with Rett syndrome behave
like mouse iPSCs in that reactivation of the inactive X chromo-some occurs during reprogramming and that random XCI can
then subsequently occur during differentiation (Marchetto
et al., 2010). However, other studies have concluded that
early-passage hiPSC lines contain an inactive X (Xi) chromo-
some and that this Xi may be the same Xi originally contained
within the somatic cell that was reprogrammed (Pomp et al.,
2011; Tchieu et al., 2010). If X-linked models of human disease
are to be properly interpreted, it will be critical to resolve how
the X chromosome is regulated in female hiPSCs.
Lesch-Nyhan syndrome (LNS) is caused by mutations in the
X-linkedHPRT gene and is characterized by profound behavioral
and neurological symptoms, including mental retardation, self-
mutilation, and motor dysfunction (Jinnah, 2009; Visser et al.,
2000). LNS is generally observed in HPRT/Y males, whereas
HPRT+/ carrier females are generally nonsymptomatic. Muta-
tions in HPRT interfere with the purine salvage pathway (Bau-
meister and Frye, 1985; McDonald and Kelley, 1971). However,
it is unknown whymutations in this pathway most severely affect
the nervous system. Unfortunately, HPRT mutant mice do not
recapitulate many of the neurological phenotypes observed in
patients (Engle et al., 1996; Finger et al., 1988). We reasoned
that derivation of hiPSC lines from individuals with HPRT muta-
tions might allow a robust human cellular model of LNS to be
established. Furthermore, because mutations in HPRT allow
for isolation of somatic cells with a given status of XCI, we
hypothesized that LNS hiPSCs might also allow resolution of
the ambiguity surrounding XCI during human reprogramming.
Here, we report that hiPSCs can be used to generate an in vitro
model for LNS. Additionally, our results confirm that early
passage female hiPSC lines contained an inactive X chromo-
some (Pomp et al., 2011; Tchieu et al., 2010) and that this inactive
chromosomewas in every case the same inactive X chromosome
found in the somatic fibroblast that they were derived from.
However, as we subjected these hiPSCs to long-term culture,
we found that female cell lines lost foci of both histone H3
lysine-27 trimethylation (H3K27me3) and XIST RNA and that
these events coincided with ectopic reactivation of the functional
HPRT gene from the inactive X. We further show that this
‘‘erosion’’ of dosage compensation was not reversed by either
differentiation or another round of reprogramming, and hadCell Stem Cell 10, 595–609, May 4, 2012 ª2012 Elsevier Inc. 595
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LNS. Consequently, female lines that have lost XCI marks no
longer exhibited the LNS phenotype when differentiated into
neurons. Through multiple lines of evidence, including functional
assays of HPRT activity and analysis of X chromosome-wide
levels of DNA methylation and transcription, we show that
erosion of dosage compensation results in the gradual derepres-
sionof the vastmajority of genesnormally subjected toXCI. Thus,
if hiPSCs are to be used for disease modeling of X-linked disor-
ders, it will be critical to carefully monitor their state of XCI.RESULTS
Reprogramming Does Not Change XCI Status
To create a stem cell model for LNS, we used retroviral transduc-
tion to generate hiPSC lines by using fibroblasts isolated from
a mutant male patient (HPRT/Y) (Dimos et al., 2008; Takahashi
et al., 2007). We designated these mutant male hiPSC lines
LNS-1 and LNS-2. As further controls, we also derived several
new male hiPSC lines from BJ fibroblasts and designated these
lines WT-M-1 and WT-M-2. We also produced control female
hiPSC lines from wi-38 fibroblasts and named these lines WT-
F-1 throughWT-F-3 (Figures 1A–1C; Figures S1 and S2 available
online). In addition, for some experiments, we used the male
control hiPSC line 20b, which we have recently described (Boult-
ing et al., 2011).
Because it has been suggested that XCI can be exploited to
generate isogenic control and experimental hiPSC lines (Cheung
et al., 2011; Tchieu et al., 2010), we also generated hiPSCs from
the patient’s phenotypically normal mother (HPRT+/). HPRT+/
fibroblasts from this woman would be expected to be composed
of two cell types, those that had chosen the functional HPRT
allele for inactivation (XaHPRTXiHPRT+) and those that had inacti-
vated the mutant allele (XaHPRT+XiHPRT). It is known that cells
selecting the functional HPRT allele for inactivation, and there-
fore lacking HPRT activity, are resistant to the toxic nucleotide
analog 6-thio-guanine (6TG). Conversely, cells that express the
functional HPRT allele can grow in the presence of hypoxan-
thine, aminopterin, and thymidine (HAT)-containing medium.
We used this biochemical distinction between cells in the popu-
lation to select fibroblasts with a known inactive X status, using
HAT selection to isolate homogenous populations of XaHPRT+
XiHPRT fibroblasts and 6TG to select for fibroblasts that were
XaHPRTXiHPRT+ (Figures 1A and S1).
To monitor the fate of the inactive X chromosome during
reprogramming of female fibroblasts, we produced hiPSCs byFigure 1. Generation of hiPSC Lines from LNS-Affected Males and Ca
(A) Strategy for generating fibroblasts with a known inactive X chromosome for r
(B) XIST FISH and NANOG/H3K27me3 staining for new hiPSC lines at passage
derived from 6TG-treated fibroblasts; CR-HAT 1-4, iPSC lines derived from HAT-t
Scale bars represent 10 mm.
(C) Quantification of NANOG-positive cells with H3K27me3 foci and XIST cloud at
adult fibroblasts (hFib).
(D) Crystal violet staining of newly derived HPRT+/+ or HPRT/Y hiPSC lines at pa
(E) Quantification of hiPSC colonies that are HAT or 6TG resistant in wild-type an
(F) Crystal violet staining of newly derived HPRT+/ hiPSC lines at passage 6 aft
(G) Quantification of hiPSC colonies that are HAT or 6TG resistant in four hiPSC
6TG-selected fibroblasts (CR-6TG-1-8).
See also Figures S1 and S2 for additional data.retroviral transduction (Takahashi et al., 2007) by using several
distinct populations of fibroblasts.We reprogrammed fibroblasts
that were subjected to HAT selection, fibroblasts subjected to
6TG selection, and the original nonselected, female carrier
fibroblasts (Figures S1 and S2). We named the female hiPSC
lines derived from the nonselected fibroblasts CR-1 through
CR-3 to designate their carrier status. hiPSC lines derived
from HAT-selected fibroblasts were named CR-HAT-1 through
CR-HAT-4, and lines from 6TG-selected fibroblasts were named
CR-6TG-1 through CR-6TG-8. To determine the X-inactivation
status of these new hiPSC lines, we performed XIST RNA FISH
as well as costained cultures with antibodies specific to NANOG
and H3K27me3 (Figures 1B and 1C). Male hiPSCs and fibro-
blasts exhibited neither foci of H3K27me3 nor a ‘‘cloud’’ of
XIST RNA (n = 3 hiPSC lines, n = 2 fibroblasts) (Figures 1A and
1B). In contrast, each of the low-passage (p5-6) female hiPSC
lines was homogenously composed of cells that displayed
a cloud of XIST and a focus of H3K27me3, similar in appearance
and frequency to those found in female fibroblasts (n = 10 hiPSC
lines, n = 2 fibroblast lines) (Figures 1B and 1C).
To examine whether there had been transient reactivation of
the Xi during reprogramming or whether instead they had re-
tained the same Xi of the fibroblasts they were generated from,
we exposed the newly generated hiPSCs to both HAT and 6TG
selection (Figures 1D–1G). As expected, male HPRT/Y (LNS-1
and LNS-2) hiPSCs were HAT sensitive and 6TG resistant,
whereas wild-type male HPRT+/Y (WT-M1) and female HPRT+/+
(WT-F1) lines were HAT resistant and 6TG sensitive (Figures
1D and 1E). When we analyzed low-passage hiPSC lines gener-
ated from drug-selected HPRT+/ fibroblasts (CR-HAT-1
through -4 and CR-6TG-1 through -8), we found in all cases
that they were uniformly composed of cells that retained the
same drug resistance profile as the fibroblasts they were derived
from (n = 12/12 lines at p5-6) (Figures 1F and 1G). In none of the
cases did we observe ‘‘switching’’ of a cell line’s drug resistance
status, which would have been indicative of a change in XCI
status. Thus, our study corroborates recent studies (Pomp
et al., 2011; Tchieu et al., 2010) suggesting that hiPSCs inherit
the inactive X of the donor cell they were produced from.HPRT-Deficient hiPSC Lines Produce Abnormal
Neuronal Cultures
To begin investigating whether disease-specific hiPSC lines
might be used to model LNS, we performed embryoid body
(EB)-mediated neuronal differentiation and then stained cultures
with antibodies specific to the neuronal antigens TUJ1, MAP2A,rrier Females
eprogramming to hiPSCs and results.
5–6. CR, female carrier lines for the HPRT mutation; CR-6TG-1-8, iPSC lines
reated fibroblasts; LNS 1-2, iPSC lines derived from HPRT/Y male fibroblasts.
passage 6 in newly derived hiPSC lines and in control male and female human
ssage 6 after treatment with media containing HAT or 6TG.
d HPRT-deficient male hiPSC lines.
er treatment with media containing HAT or 6TG.
lines from HAT-selected fibroblasts (CR-HAT-1-4) and eight hiPSC lines from
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Figure 2. Neuronal Differentiation of HPRT-Deficient hiPSCs Can Be Used to Model LNS
(A) Neuronal differentiation of HPRT-positive and -negative hiPSCs and our results (RA, retinoic acid).
(B) Neurons generated from the HPRT-positive, wild-type male hiPSC line 20b, stained for TUJ1. Scale bar represents 50 mm.
(C) Neurons generated from the HPRT mutant male hiPSC line LNS-2 stained for TUJ1. Scale bar represents 50 mm.
(D) Quantification of TUJ1-positive neurons and average neurite length in neuronal cultures generated fromHPRT+ lines hiPSC 20b and hESCHUES 51, alongside
diseased HPRT lines LNS-1 and LNS-2. Error bars represent mean ± SD.
(E) Neurons derived from the LNS-2-HPRTresc hiPSC line that was transduced with lenti virus carrying the intact HPRT cDNA, stained for TUJ1. Scale bar
represents 50 mm.
(F) Neurons derived from the LNS-2-VecCNTRL hiPSC line that was transduced with an empty lenti virus, stained for TUJ1. Scale bar represents 50 mm.
(G) Quantification of TUJ1-positive neurons and average neurite length in neuronal cultures generated from two independently derived LNS-2 HPRT rescue lines
(LNS-2-HPRTresc-A and B) and from the vector control hiPSC line (LNS-2-VecCNTRL). Error bars represent mean ± SD.
(H) Neurons generated from female carrier, HPRT-positive, phenotypically wild-type hiPSC CR-HAT-1 at passage 20, stained for TUJ1. Scale bar represents 50 mm.
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Strikingly, we found that HPRT/Y hiPSC lines LNS-1 and
LNS-2 (n = 2 lines) produced significantly fewer neurons than
control wild-type hiPSC and human embryonic stem cell
(hESC) lines. In addition, the neurons that were generated by
these LNS lines displayed significantly shortened neurites rela-
tive to the neurons produced from control hiPSCs (Figures 2A–
2D). This LNS ‘‘neuronal phenotype’’ was not significantly
affected by coculture with neural supportive glial cells (Figures
S3B–S3C).
Recently, we have shown that distinct hiPSC lines, even lines
derived from the same individual, can display variable propensi-
ties for differentiation down the neuronal lineage (Boulting et al.,
2011). We therefore reasoned that a definitive means of deter-
mining whether the differences we observed in neuronal cultures
were the result of varying levels of HPRT activity was to restore
HPRT activity in mutant lines and see whether this rescued
neuronal number and neurite length to control levels. To this
end, we transduced the HPRT-deficient LNS-2 male hiPSC line
with either a control lentiviral vector or an identical vector
harboring the HPRT cDNA. To determine whether transduction
with the HPRT lentivirus could restore HPRT activity to the cells,
we exposed the HPRT-transduced (LNS-2-HPRTresc) and
control transduced (LNS-2-VecCNTRL) LNS-2 cell line to HAT
selection (Figure S4A). Like the parental LNS-2 line, the line sub-
jected to control transduction remained HAT sensitive, whereas
the line transduced with the HPRT vector produced HAT-resis-
tant colonies. To determine whether rescue of HPRT activity
was sufficient to rescue the neuronal phenotype, we differenti-
ated two independently generated rescue sublines (LNS-2-
HPRTresc-A and LNS-2-HPRTresc-B) side by side with the
vector-only control line (LNS-2-VecCNTRL). As expected, the
LNS-2-VecCNTRL hiPSC line produced neuronal cultures with
few neurons that possessed short neurites, whereas each of
the two rescued LNS-2-HPRTresc hiPSC lines produced
neuronal cultures that contained significantly more neurons
with significantly longer neurites. In fact, the transgenic rescue
restored these properties to those found with wild-type control
hiPSCs (Figures 2E–2G and S4B).
As another means of demonstrating that the phenotypes we
observed were due to loss of HPRT function, we tested the
disease modeling utility of our isogenic female carrier lines. For
these experiments, we assayed neuronal cultures derived from
both HAT-resistant wild-type (XaHPRT+XiHPRT) line CR-HAT-1
and 6TG-resistant ‘‘mutant’’ (XaHPRTXiHPRT+) lines CR-6TG-2
and CR-6TG-3. As one might predict by their pattern of XCI,
the low-passage XaHPRT+XiHPRT CR-HAT-1 line generated
normal neuronal cultures that were comparable to WT control
lines. In contrast, the low-passage XaHPRTXiHPRT+ cell lines
CR-6TG-2 and CR-6TG-3 behaved like HPRT/Y mutant male
lines, producing significantly fewer neurons, with significantly
shorter neurites (Figures 2H–2J). As these cell lines were
isogenic, other than expression of X-linked genes, these results
further support the notion that the differences in the neuronal(I) Neurons derived from of the isogenic female carrier, HPRT-negative, ‘‘mutant’’
(J) Quantification of TUJ1-positive neurons and average neurite length in neuron
Error bars represent mean ± SD.
Statistical significance was analyzed with two-tailed Student’s test; *p < 0.05, **cultures we observed were not the derivative of autosomal
genetic variation among the iPSC lines.
Overall, our findings suggest that hiPSCs can provide a model
for studying the neuronal basis of LNS that overcomes limitations
of models that have been previously described (Cristini et al.,
2010; Guibinga et al., 2010).
Dosage Compensation Gradually Erodes in Female
hiPSC Lines
Although we observed what seemed to be normal dosage
compensation in low-passage hiPSC, as we expanded these
cells lines, we found that an ever-increasing portion of cells
within each line gradually lost H3K27me3 foci and XIST clouds
(Figures 3A, 3C, and 3G). It has been suggested that loss of these
marks of XCI in somatic cells and in human pluripotent stem cells
does not directly result in loss of dosage compensation (Brown
and Willard, 1994; Csankovszki et al., 2001; Silva et al., 2008;
Tchieu et al., 2010). However, when we used the HAT and 6TG
selections to assay for the functional state of HPRT activity
over time in culture, we observed that originally homogeneous
6TG-resistant cells lines (XaHPRTXiHPRT+) such as CR-6TG-2
gradually became ‘‘mixed’’ cell lines composed of both HAT-
resistant and 6TG-resistant subpopulations. These mixed cell
lines eventually converted into cell cultures that were completely
HAT resistant. This gradual transition in HPRT activity was
observed in three out of three independent hiPSC lines and
was strongly correlated with the loss of H3K27me3 foci and
loss of XIST clouds (Figures 3B–3D and 3G). Loss of thesemarks
of XCI over time was not due to selective pressure to reactivate
HPRT expression, as we observed that HAT-resistant isogenic
(XaHPRT+XiHPRT) lines such as CR-HAT-1 and CR-HAT-2 also
lost foci of H3K27me3 over time in culture (Figure S5A).
We reasoned that there were two potential models that could
explain our finding. (1) As we cultured these hiPSC lines, they
gradually reactivated their inactive X, becoming further reprog-
rammed and more like mouse ESCs, as has been suggested
(Chin et al., 2009). Or (2) as we passaged these lines, loss of
XCI marks was occurring inappropriately, as has been observed
in certain hESC lines (Dvash et al., 2010; Enver et al., 2005; Shen
et al., 2008; Silva et al., 2008).
To begin distinguishing between these two models, we first
examined whether low-passage (XIST+) and high-passage
(XIST) cell lines were equivalently reprogrammed. Important
indicators of the extent of reprogramming include the examina-
tion of whether retroviral transgenes encoding pluripotency
factors have been silenced and whether transcription of their
endogenous genetic counterparts has been activated. Quantita-
tive RT-PCR analysis indicated that even in low-passage hiPSC
lines, expression of retroviral OCT4, SOX2, and cMYC had been
extinguished, while expression of the endogenous loci had been
induced to levels similar to those found in both late-passage
hiPSC lines, established hiPSC lines, and hESC lines (Fig-
ure S5B). Although we did detect modest levels of viral KLF4
expression in all of our hiPSC lines, transcriptional levels wereiPSC CR-6TG-3 at passage 13, stained for TUJ1. Scale bar represents 50 mm.
al cultures derived from isogenic HPRT-positive and -negative female iPSCs.
p < 0.01, ***p < 0.001. See also Figures S3 and S4 for additional data.
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Figure 3. Female hiPSC Lines Lose Marks of XCI with Time in Culture and Ectopically Express HPRT from the Xi
(A) Diagram depicting our observation that dosage compensation erodes on the X chromosome over time in culture.
(B) Crystal violet staining of hiPSC line CR-6TG-2 at early, mid, and late passages, after treatment with either HAT or 6TG.
(C) Quantification of H3K27me3 foci in NANOG-positive cells for hiPSC lines show decrease in XCI marks over time in culture.
(D) Quantification of 6TG- and HAT-resistant colonies for hiPSC lines over time in culture.
(E) Diagram depicting our observation that hiPSC lines do not change their XCI state during differentiation.
(F) Crystal violet staining of differentiated cells generated from female hiPSC lines that were originally HPRT negative (XaHPRTXiHPRT+), with different proportions
of XIST.
(G) Quantification of XIST clouds in hiPSC lines and their differentiated derivatives.
See Figure S5 for additional data.
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line, suggesting that they were independent of the extent of re-
programming. Thus, even our low-passage lines were
sufficiently reprogrammed to have silenced the transgenes that
encode for core reprogramming factors and to have activated
expression of endogenous loci involved in regulating pluripo-
tency. These findings suggest that ongoing reprogramming, as
measured by this assay, was not likely to be the cause of the shift
in X-linked gene expression we observed.
It has been suggested that under certain culture conditions,
hiPSCs can take on properties more similar to mouse ESCs600 Cell Stem Cell 10, 595–609, May 4, 2012 ª2012 Elsevier Inc.(Hanna et al., 2010) and that this may change their state of XCI
aswell as eliminate their dependence on Tgf-b and FGF signaling
for self-renewal (Hanna et al., 2010). To determine whether our
hiPSCs were taking on more ‘‘naive’’ properties, we asked
whether their self-renewal was still dependent on Tgf-b and
FGF signaling. To this end, we carried out colony-forming assays
with each line at both low and high passages, in the presence
and absence of chemical inhibitors of Tgf-b and FGF signaling.
We found that regardless of whether we inhibited Tgf-b or FGF
signaling, colony formation was similarly compromised at both
low and high passage, suggesting that our cell lines were not
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Erosion of Dosage Compensation Impacts Human iPSCstaking on more ‘‘naive’’ characteristics as they lost XCI marks
(Figure S5C).
As an additional means of testing whether our cells were
taking on a more ‘‘naive’’ mouse-like character, we asked
whether, as in mouse pluripotent stem cells, XCI would take
place upon differentiation of lines that lost marks of the inactive
X. We carried out differentiation experiments both in vitro and
in vivo within teratomas. Initially, we took individual passages
of hiPSC lines that were originally uniformly XaHPRTXiHPRT+
but had acquired declining levels of XCI marks, split each batch
of cells in half, and then carefully quantified XCI status by XIST
FISH in the first half of the cells. We then took the second half
of the batch of each passage of cells, differentiated them within
EBs, then again quantified their XCI status by XIST FISH as well
as assessed their state of HPRT activity (Figures 3E–3G). We
found that low-passage hiPSCs that were 6TG resistant and
possessed an inactive X (XaHPRTXiHPRT+) produced 6TG-resis-
tant, HAT-sensitive differentiated cells, with an inactive X, indi-
cating that they continued to maintain the same inactive X
throughout differentiation. However, when we differentiated
later passages of the same lines that had become HAT resistant,
lost XIST expression, and had derepressed HPRT expression
from the Xi, the resulting differentiated progeny were also
devoid of XIST and remained HAT resistant and 6TG sensitive
(Figures 3E–3G).
We next proceeded to determine whether in vivo differentia-
tion in the context of a long-term teratoma was able to reset
XCI in hiPSC lines that had lost XIST clouds. To this end, we
injected a passage of the CR-6TG-2 cell line that had become
devoid of clouds of XIST RNA, as well as passages of the
CR-6TG-3 and CR-HAT-1 lines that still retained XIST expres-
sion, into nude mice. After teratoma formation, we examined
differentiated cells from each teratoma for marks of XCI. As
predicted by our in vitro differentiation experiments, hiPSCs
that contained XIST clouds produced teratomas containing cells
that retained XIST clouds. However, hiPSC lines that had lost
XIST clouds produced teratomas containing cells that remained
devoid of XIST clouds (Figure S5D). Thus, these results show
that once foci of H3K27me3 and XIST clouds had been lost
and HPRT expression was derepressed in a hiPSC line, it could
not be restored by differentiation, either in vitro or in vivo.
In aggregate, our results suggest that instead of becoming
more like mouse ESCs, our hiPSCs were undergoing a sort of
‘‘erosion’’ of dosage compensation. Although this process
seemed indicative of an epigenetic rather than a genetic
phenomenon, we did ask whether mutations in protein-coding
portions of the genome might have accumulated during either
reprogramming or the passaging process that could have
contributed to the effect. For this purpose, we took passages
of the hiPSC lines 29A and 29e (Boulting et al., 2011) that had
recently been subjected to whole-exome sequencing (Gore
et al., 2011) and assessed whether they still contained marks
of XCI. We found that both lines were largely devoid of cells
that still contained XIST clouds and H3K27me3 foci and that
these lines did not harbor any common mutations that could
be contributing to the erosion of XCI we observed (Figures S5E
and S5F).
From these experiments, we can conclude that XCI in female
hiPSC lines does not behave similarly to that in mouse ESCsor iPSCs. Instead, it seems that although low-passage
XaHPRTXiHPRT+ hiPSCs differentiate into cells that are also
XaHPRTXiHPRT+, over time inculture, thecells gradually underwent
a process of transcriptional derepression on their inactive X.
We have termed this process ‘‘erosion’’ of dosage compensa-
tion (Xe, Xeroded). As hiPSCs were cultured, they eventually
became more and more homogeneously XaHPRTXeHPRT+.
These XaHPRTXeHPRT+ cells did not regain dosage compensa-
tion upon differentiation and instead became differentiated cells
that were also XaHPRTXeHPRT+ (Figures 3A and 3E).
Erosion of Dosage Compensation in hiPSCs Impacts
LNS Disease Modeling
We next asked whether the erosion of dosage compensation we
had observed could affect the phenotype of our LNS disease
model. We performed neuronal differentiation by using esca-
lating passages of two ‘‘mutant’’ female carrier hiPSC lines
that had each initially been uniformly composed of cells with
the inactive X carrying the normal HPRT allele (XaHPRTXiHPRT+)
(Figures 4A–4C). At low passage, both of these cell lines
produced neuronal cultures with a phenotype similar to those
exhibited by mutant male neurons (Figures 4B, 4C, and 4F).
However, when we differentiated later passage of the same
lines that had begun to undergo erosion of dosage compensa-
tion, the resulting neuronal cultures contained a mixture of
neurons that displayed the mutant phenotype and a mixture of
neurons that appeared normal (Figures 4D, 4F, and S6). Exami-
nation of XCI by staining for H3K27me3 in these neuronal
cultures demonstrated that neurons with a mutant phenotype
tended to contain marks of an inactive X, whereas neurons
that displayed a more wild-type appearance had lost their
focus of H3K27me3, suggesting that erosion of dosage compen-
sation had occurred (Figure S6). When yet-higher-passage
cultures of hiPSC that had lost all marks of XCI were differenti-
ated, the resulting neuronal cultures were indistinguishable
from those produced from wild-type (HPRT+) hiPSCs (Figures
2, 4E, and 4F).
We reasoned that the shifting phenotype we observed could
have been due to some independent or unexplained function
of increased passage that was unrelated to dosage compensa-
tion. To rule out this possibility, we began with an intermediate
passage hiPSC line that was a mixture of 6TG-resistant
(XaHPRTXiHPRT+) and HAT-resistant (XaHPRTXeHPRT+) cells.
We then used 6TG selection to purify the XaHPRTXiHPRT+ sub-
population and HAT selection to purify the XaHPRTXeHPRT+
subpopulation (Figures S7A and S7B). We confirmed that the
6TG-resistant population was uniformly composed of cells with
an inactive X, whereas the HAT-resistant population was
composed of cells that lacked H3K27me3 foci and XIST clouds
(Figure S7C). When we performed neuronal differentiation of
these two distinct subpopulations, the 6TG-resistant XaHPRT
XiHPRT+ cells exhibited the mutant phenotype. In contrast, the
neuronal cultures produced from the HAT-resistant XaHPRT
XeHPRT+ subpopulation were again identical to normal ‘‘wild-
type’’ controls (Figures S7D–S7F). Therefore, we conclude
that the erosions of dosage compensation we observed at the
HPRT locus was not reversed by neuronal differentiation and
as a result eliminated the LNS-related neuronal phenotype
originally observed upon differentiation of this cell line.Cell Stem Cell 10, 595–609, May 4, 2012 ª2012 Elsevier Inc. 601
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Figure 4. Erosion of Dosage Compensation Affects LNS Neuronal Disease Phenotypes
(A) Diagram depicting our observation that erosion of dosage compensation rescues the neuronal phenotype caused by the X-linked HPRT mutation.
(B) Neurons derived from hiPSC line CR-6TG-3 at low passage stained for TUJ1. Scale bar represents 50 mm.
(C) Neurons derived from of the hiPSC line CR-6TG-2 at low passage stained for TUJ1. Scale bar represents 50 mm.
(D) Neurons derived from higher-passage hiPSC CR-6TG-3 that have undergone erosion of XCI in a portion of their cells, stained for TUJ1. Scale bar represents
50 mm.
(E) Neurons derived from higher-passage hiPSC CR-6TG-2 that have undergone erosion of dosage compensation in all their cells, stained for TUJ1. Scale bar
represents 50 mm.
(F) Quantification of TUJ1-positive neurons and neurite length in neuronal cultures derived from lower and higher passages of hiPSC lines CR-6TG-2 and
CR-6TG-3. Error bars represent mean ± SD. Statistical significance was analyzed with two-tailed Student’s test; *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figures S6 and S7 for additional data.
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of Variation among Human Pluripotent Stem Cell Lines
To determine whether the derepression of gene silencing we
observed for HPRT was reflective of broader erosion in dosage
compensation, we turned to a large data set of genome-wide
DNA methylation and transcriptional profiles that we reported
recently (Bock et al., 2011). This data set catalogs genome-
wide DNA methylation patterns and gene expression levels for
20 hESC lines and 12 hiPSC lines (Bock et al., 2011; Boulting
et al., 2011). Although we had previously noted that nearly
50% of the loci with highest variation in DNA methylation were
located on the X chromosome (Bock et al., 2011), we had not
explored the functional ramifications of this finding.
Interestingly, when we focused our analysis specifically on
female pluripotent cell lines, 36.1% of gene promoters with the602 Cell Stem Cell 10, 595–609, May 4, 2012 ª2012 Elsevier Inc.most variable methylation were found on the X chromosome.
In contrast, only 4.6%of themost variablymethylated promoters
were found on the X chromosome in male cell lines (Figure 5A).
This sex-specific difference was also clearly detectable when
we plotted the promoter-associated levels of DNA methylation
variation for male lines against female cell lines (Figure 5B).
We also found that the vast majority of gene promoters that
exhibited substantially higher levels of DNAmethylation variation
in female compared tomale cell lines (box II in Figure 5B)were not
only located on the X chromosome (Figure 5B) but also subject
to X inactivation (Figure 5C). Furthermore, these promoters ex-
hibited characteristics consistent with genomic regions known
to be effectively repressed by DNA methylation (Figure 5D). In
contrast, those X-linked gene promoters that exhibited similar
levels of variation in male and female cell lines (box I in Figure 5B)
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Figure 5. Loss of X Inactivation Is Widespread among Human ESC and iPSC Lines
(A) Percentageof themostDNA-methylation-variable genepromoters that are locatedon theXchromosome, separately shown for femaleESC/iPSC lines (left) and
for male ESC/iPSC lines (center). For comparison, the background distribution of all gene promoter regions with sufficient DNA methylation data is shown (right).
(B) Correlation between DNA methylation variation among female ESC/iPSC lines and DNA methylation variation among male ESC/iPSC lines. Variation was
measured as the standard deviation of promoter methylation levels and plotted for all genes with sufficient DNAmethylation data. Dark blue regions indicate high
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Erosion of Dosage Compensation Impacts Human iPSCswere more likely to evade X inactivation and were characterized
by distinct gene promoter properties (Figure 5D). A full list of
genes with promoters that are subject to erosion of dosage
compensation (box II in Figure 5B) and those that seem more
recalcitrant to the effect (box I in Figure 5B) have been listed in
Table S1. Overall, 91% of the genes known to be subject to
X inactivation with sufficient information for us to examine dis-
played this variable promoter methylation (Figure 5C).
Consistent with our findings in LNS hiPSCs, we observed that
female pluripotent cell lines varied in their XIST expression levels
(Figure 5E). The cell line-specific differences in X inactivation
status appeared to have widespread functional consequences:
Female lines with low XIST expression were characterized by
a chromosome-wide increase in X-linked transcription relative
to male lines (Pearson’s r = 0.70) (Figure 5F). In addition, we
observed a significant negative correlation between the average
promoter of DNA methylation levels and the average gene
expression levels for all X-linked genes in female hESC and
hiPSC lines (Pearson’s r = 0.35) (Figure 5G). This latter finding
suggests that erosion of dosage compensation involves tran-
scriptional derepression and loss of the associated promoter
DNA methylation.
We next decided to take advantage of our genomic analysis to
determine whether expression levels of other X-linked
loci commonly mutated in disease were similarly affected by
this phenomenon. If so, it would suggest that the erosion of
dosage compensation reported here and its negative impact
on modeling LNS would extrapolate to those conditions as
well. To this end, we compared five human pluripotent stem
cell lines with high XIST levels to five stem cell lines with little
or no XIST expression. We plotted the levels of transcription of
eight such genes found in distinct regions of the X chromosome
(HCCS, PDHA1, RPGR, CAST, COL4A5, PRPS1, HPRT,
MECP2) in a given cell line against that cell line’s average relative
gene promoter methylation (Figures 6A–6C). It was immediately
apparent that many female cell lines that had lost XIST expres-
sion had demethylated their former Xi and had derepressed
expression of these disease-specific genes (Figure 6C). This
suggests that the use of hiPSCs for disease modeling would
also be impacted for at least these additional genes.
In summary, our bioinformatic analyses show that the majority
of female pluripotent cells exhibit signs of erosion in dosage
compensation. Furthermore, loss of XIST expression in thepoint densities, and black crosses denote genes that map to the X chromosom
ESC/iPSC lines.
(C) Overlap between genes that are subject to consistent X inactivation (left) and g
in female ESC/iPSC lines (right). Significance was established with Fisher’s exact
human X chromosome (Carrel and Willard, 2005).
(D) Promoter characteristics of X-linked genes with low versus high levels of DNA
and II in (E). The table summarizes the results of an EpiGRAPH analysis (Bock
depletion between the two sets of gene promoter regions.
(E) XIST expression levels in male and female hESC, hiPSC, and human fibroblas
a scale from 0 (no expression) to 10 (maximal expression) across all genes.
(F) Correlation between cell-line-specific XIST expression levels and mean ge
(Bock et al., 2011). A linear regression linewas calculated across all female ESC/iP
the bottom right of the diagram.
(G) Correlation between mean DNA methylation levels across all X-linked gene pr
DNAmethylation and gene expression data for 20 ESC lines, 12 iPSC lines, and 6 fi
of human pluripotent cell lines (Bock et al., 2011).
See also Table S1 for additional data.
604 Cell Stem Cell 10, 595–609, May 4, 2012 ª2012 Elsevier Inc.female pluripotent cells did not simply modify the expression
of only a small number of genes, but instead appeared to lead
to a broad derepression of X-linked genes. This increase in
X-linked expression levels is also correlated with widespread
loss of repressive DNA methylation from the (formerly inactive)
X chromosome. Thus, our data demonstrate that erosion of
dosage compensation in hiPSCs not only is relevant to the study
of LNS but has a broad range of implication for the study of many
X-linked diseases.
Once Dosage Compensation Has Eroded, Further
Reprogramming Cannot Restore It
We have thus far demonstrated that during prolonged culture
female pluripotent cells undergo gradual erosion in dosage
compensation that cannot be restored by differentiation. We
next considered whether further reprogramming might restore
normal dosage compensation. We took an XaHPRTXiHPRT+
hiPSC line that was 6TG resistant, as well as HAT-resistant
derivatives of this line that had undergone XCI erosion
(XaHPRTXeHPRT+), differentiated both lines into embryonic fibro-
blasts, transduced them with reprogramming retroviruses, and
selected secondary hiPSC lines. We then analyzed the very first
passages of the resulting secondary hiPSC lines for both HPRT
gene activity and for the presence of marks of the inactive X,
H3K27me3 foci, and XIST clouds (Figures 7A and 7B). Regard-
less of whether it was at low-oxygen (physiological) or high-
oxygen (atmospheric) conditions, when we performed a second
round of reprogramming on cells that had an inactive X, the
secondary hiPSCs again maintained the inactive X that had
been silent in both their primary fibroblast and hiPSCs predeces-
sors. In contrast, when we performed an additional round of
reprogramming on cells that had undergone erosion of dosage
compensation, the secondary derivatives of these cells also
displayed eroded dosage compensation, did not restore marks
of XCI, and continued to ectopically express HPRT from what
was originally the Xi (Figures 7A–7C and 7E).
Furthermore, we found that the failure of reprogramming to
restore the inactive X chromosomewas not unique to derivatives
of hiPSCs but also held true for reprogramming of fibroblasts
derived from hESCs. When we took fibroblasts derived from
high-passage HUES 37 cells that had eroded XCI, reprogram-
ming could restore neither XIST clouds or foci of H3K27me3
(Figures 7D and 7E).e. Boxes I and II highlight genes with low versus high variation among female
enes that exhibit high levels of promoter-associated DNAmethylation variation
test. X-inactivation data were obtained from a comprehensive mapping of the
methylation variation among female ESC/iPSC lines, as indicated by boxes I
et al., 2011) testing 1,000 genomic attributes for significant enrichment or
t (hFib) cell lines, based on microarray data (Bock et al., 2011) and relative to
ne expression levels across all X-linked genes, based on microarray data
SC lines (red) and the corresponding Pearson correlation coefficient is shown at
omoters and mean gene expression levels averaged across all X-linked genes.
broblast cell lines were obtained from a recent study reporting a referencemap
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Here, we have demonstrated that HPRT-null male hiPSC lines
can be used to produce a new robust model system for the
study of Lesch-Nyhan syndrome. The development of this
cellular-based human LNS model is in and of itself significant,
as previous efforts to model this condition in the mouse have
been unsuccessful (Engle et al., 1996; Finger et al., 1988). Our
experiments clearly demonstrate that the loss of HPRT activity
directly results in a significant loss of neurons and decrease in
neurite length. Moreover, we show that these neuronal defects
are cell autonomous and can be rescued by exogenous expres-
sion of the functional HPRT. It remains unclear why the malfunc-
tion in HPRT affects most severely the neuronal tissue, and
whether the purine salvage pathway plays a significant role in
these cells or if HPRT-deficient neurons are merely more sensi-
tive to the accumulation in uric acid or other environmental
stressors. Our system provides a platform where these ques-
tions can now be further explored.
We have further shown that XaHPRTXiHPRT+ female hiPSC
lines with proper dosage compensation also produce the LNS
neuronal phenotype seen with male lines. However, over time
in culture, we observed a gradual decrease in the frequency of
female hiPSCs that contained XIST and H3K27me3 foci, which
was highly correlated with ectopic HPRT expression from the
inactive X. Although others have noted variation between cell
lines in the proportion of human pluripotent cells with these
XIST and H3K27me3 marks (Lengner et al., 2010; Shen et al.,
2008; Silva et al., 2008; Tchieu et al., 2010), the functional rami-
fication of losing XIST expression has not been previously
explored. The lack of motivation for investigating this phenom-
enon might be explained by studies in both the mouse and in
human somatic cells which demonstrated that even when XIST
expression was eliminated from the inactive X, repressive DNA
methylation and transcriptional repression were retained (Brown
and Willard, 1994; Csankovszki et al., 2001). However, we found
that in human pluripotent stem cell lines, this does not seem to
be the case. Instead, our findings demonstrated that loss of
XIST and the heterochromatin modifications of the inactive X in
female stem cells were associated with chromosome-wide
erosion in dosage compensation.
Our studies have shown that erosion in dosage compensation
is not a benign effect and instead has substantial ramifications
for the utility of human pluripotent stem cell lines. These results
clearly demonstrate that this loss of dosage compensation can
occlude the LNS phenotypes and may interfere with the use of
hiPSCs for the study of other X-linked diseases. Furthermore,
our bioinformatic analyses suggest that this phenomenon prob-
ably affects most of the genes subject to XCI (91%) we examined
and that this seems to be a universal effect impacting many
pluripotent stem cell lines.
Extrapolating from our experience with modeling the X-linked
disease Lesch-Nyhan syndrome and based on our genomicFigure 6. Erosion of Dosage Compensation Affects Many Disease-Link
(A) Diagram of the human X chromosome and location of eight X-linked disease-
(B) Five female hESC and hiPSC lines with high XIST expression and five female
erosion of X-linked disease genes in (A).
(C) Correlation between mean promoter DNA methylation levels and gene expre
606 Cell Stem Cell 10, 595–609, May 4, 2012 ª2012 Elsevier Inc.analysis, we predict that a similar phenomenon would occur
when using female pluripotent stem cells to model any X-linked
disease caused by mutations in genes subject to XCI. These
findings provide a potential explanation for the variations in the
Rett syndrome phenotypes, the XCI state, and MECP2 expres-
sion observed by various groups when they used XMECP2/
XMECP2+ hiPSCs for disease modeling (Cheung et al., 2011;
Kim et al., 2011; Marchetto et al., 2010).
Because erosion of dosage compensation was such a wide-
spread phenomenon among female pluripotent cell lines, and
because it seemed to have such substantial functional ramifica-
tions, we have begun to contemplate steps that might be taken
to restore proper XCI. Because differentiation of cell lines could
not restore XCI, we considered the possibility that an additional
round of reprogramming might. Unfortunately, this was not the
case, because further reprogramming did not seem to affect
the proportion of cells that did or did not contain an XIST cloud
or a focus of repressive H3K27me3. Lines with a clearly inactive
X retained it, while signs of XCI and gene silencing were not
restored to lines that displayed eroded dosage compensation.
Thus, once XCI is lost, it cannot be reestablished by standard
procedures such as in vitro differentiation or a second round of
iPSC reprogramming.
The findings reported here raise the intriguing question of
why erosion of dosage compensation is occurring in female
pluripotent cells, while it does not occur (for instance) in somatic
fibroblasts. It could be that under the rapid growth conditions,
which human pluripotent stem cells are adapted to, the expres-
sion of XIST or perhaps some other mechanistic regulator of XCI
is dynamically unstable. It is also possible that there are genes
expressed from the X chromosome that provide prosurvival or
progrowth signals for pluripotent stem cells that might select
for cells that have lost XCI. The observation that certain regions
of the X chromosome are among those most commonly dupli-
cated in stem cell lines with abnormal karyotypes is consistent
with the notion that increased X chromosome gene dosage
might have a selective advantage (Baker et al., 2007). If this is
true, there may be a selective pressure for cells to undergo
erosion of XCI.
The results reported here are consistent with Nazor and
colleagues’ studies of the genome-wide profiling of transcription
and DNA methylation levels in 205 human pluripotent cell lines
and 130 somatic controls (Nazor et al., 2012). Similar to our find-
ings, they observed that the X chromosome harbors the vast
majority of epigenetic variation between female pluripotent cell
lines and that this variation results in the derepression of specific
X-linked disease genes in as many as 60% of pluripotent
cultures.
Together our studies underscore the importance of moni-
toring epigenetic variation during the use of pluripotent stem
cells in disease modeling efforts. Although the erosion of
dosage compensation we report here would most obviously
impact X-linked disease models, it is clear that the levels ofed Genes across the X Chromosome
specific genes examined in this section.
cell lines with no XIST expression (Bock et al., 2011) chosen for comparison of
ssion for the genes in (A) and hESC/hiPSC lines in (B).
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Figure 7. Additional Round of Reprogramming Does Not Restore XCI
(A) Diagram depicting experimental approach and results obtained from reprogramming of secondary fibroblast (2nd fibroblasts) with normal or aberrant XCI
marks under both physiological (5%) and ambient (20%) oxygen conditions.
(B) XIST high and XIST low sublines of the secondary iPSC line CR-6TG-2 differentiated into secondary fibroblasts, and staining for H3K27me3/NANOG and XIST
FISH in newly reprogrammed secondary hiPSCs. Scale bars represent 20 mm.
(C) Alkaline phosphatase (AP) staining of 5% and 20% oxygen hiPSC colonies after treatment with HAT or 6TG.
(D) Human ESC line HUES 37 differentiated into secondary fibroblasts and staining for H3K27me3/NANOG and XIST FISH in iPSCs derived from HUES 37
secondary fibroblasts. Scale bars represent 20 mm.
(E) Quantification of XIST cloud in secondary fibroblasts (2nd Fibs) and secondary iPSC (2nd iPSC) under 5% or 20% oxygen.
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Erosion of Dosage Compensation Impacts Human iPSCshundreds of genes that could have modifying effects on other
disease phenotypes are also fluctuating significantly. In the
short term, it will therefore be critical to be aware of the state
of XCI in any given female cell line during its use in disease-
modeling efforts. In the longer term, it would be desirable to
identify culture conditions that can protect female cell lines
from this erosion of XCI.EXPERIMENTAL PROCEDURES
Human iPSC Derivation and Culture
Human fibroblasts were commercially obtained from Coriell Cell Repository
and ATCC and grown under standard conditions. To produce hiPSC colonies,
human fibroblasts were transduced with viruses containing OCT4, SOX2,
KLF4, and cMYC as previously described (Boulting et al., 2011; Dimos et al.,
2008). hiPSC colonies were manually picked based on morphology withinCell Stem Cell 10, 595–609, May 4, 2012 ª2012 Elsevier Inc. 607
Cell Stem Cell
Erosion of Dosage Compensation Impacts Human iPSCs3–4 weeks. All hiPSC lines were continuously cultured under standard
conditions on irradiated mouse embryonic fibroblasts and manually passaged
every 6–8 days throughout the work in this study. Differentiation of human
pluripotent stem cells was carried out by EB suspension in media containing
serum. After 8–10 days, cellswere plated onto gelatin-coated plates andgrown
for another 8–10 days before analysis. To test for dependency on FGF and
TGFb, hiPSCs were cultured in media containing the inhibitor SB431542
(Sigma) or media without FGF containing the inhibitor PD173074 (Sigma). For
the generation of rescue lines, the HPRT-negative hiPSCs, LNS-2, was plated
on matrigel (FISHER) in mTESR media (Stem Cell Technologies) and trans-
duced with virus containing the intact HPRT gene or the empty viral vector.
Cells with HPRT activity were selected with mTESR media containing HAT,
then used for neural differentiation. The derivation and use of hiPSC lines
from fibroblasts obtained from Coriell and ATCC does not constitute human
subject research because this material was not collected for this specific
research use and was deidentified to the researchers. All human ESC work
was previously approved by Harvard’s Embryonic Stem Cell Research
Oversight Committee (ESCRO). All animal research was performed under the
oversight of the Institutional Animal Care and Use Committee (IACUC) at
Harvard University.
6TG and HAT Selections
To produce pure population of HPRT or HPRT+ fibroblasts from the HPRT+/
carrier cells (Corierll: GM00026), cells were incubated with media containing
either 6TG (30–60 mM 2-amino-6-mercaptopurine; Sigma) or HAT (1 3 104 M
hypoxanthine, 4 3 107 M aminopterin, 1.6 3 105 M thymidine; Invitrogen)
respectively, for a period of 6 days. Each selected subline was then expanded
and transduced with viruses for the production of hiPSCs. To assay for HPRT
activity in established hiPSC lines, equal number of manually dissected colony
clumps were placed in three wells of a six-well plate. 2–3 days after passaging,
colonies were marked and scored to ensure equal survival of colonies used
for drug selection. Selection was carried out in standard hESC media contain-
ing either 6TG or HAT for a period of 5 to 6 days, after which cells were fixed
and stained with crystal violet. Colonies were manually scored for each drug
selection and proportion of colonies was compared to that of cells not treated
with either drug.
Differentiation of Human Pluripotent Cells into Neurons
hESCs/iPSCs were grown to 80% confluence and then manually gridded and
dissociated. Equal number of clumps were resuspended in hESC media
without bFGF or plasmanate, in low-attachment 6-well plates (Corning) in
order to form embryoid bodies (EBs). After 10 days, EBs were induced toward
neuronal identity for another 25 days by retinoic acid (1 mM, Sigma) in N2B27
media containing DMEM:F-12, 1% N2 supplement (Invitrogen), 1% B27
supplement (Invitrogen), 0.2 mM ascorbic acid (Sigma-Aldrich), 0.16%
D-Glucose (Sigma-Aldrich), 1% nonesesential amino acids (Invitrogen),
2 mM glutamax-I (Invitrogen), 50 units/ml penicillin, and 50 g/ml streptomycin
(Invitrogen). After a total of 35 days of differentiation, the EBs were dissociated
with 20 units of papain and 1,000 units of Deoxyribonuclease I (Worthington
Biochemical Corporation). The resulting single cells were then washed with
D-MEM/F12 and then resuspended in N2B27 media supplemented with neu-
rotrophic factors (GDNF, BDNF, CNTF; 10 ng/ml, R&D Systems). The cells
were counted and equal number of cells were then plated on poly-D-lysine/
Laminin 8-well CultureSlides (BD Biosciences) coated with matrigel (FISHER).
All comparative differentiation experiments were carried out with all experi-
mental lines and controls in parallel, and all stained neuronal cultures were
imaged and scored blindly. TUJ1-positive neurons and neurite lengths were
analyzed with ImageJ software.
Immunocytochemistry
Pluripotent, differentiated, or neuronal cultures were fixed in 4% paraformal-
dehyde. Fixed cultures were permeabilized with either 0.5% Tween or 0.2%
Triton-X in PBS, blocked in 10% serum, and then incubated in blocking
solution containing primary antibodies. Cells were incubated in secondary
antibodies, then washed and mounted in Vectashield with Dapi (Vector Labo-
ratories) and imaged. Alkaline phosphatase activity was detected in live
cultures with the alkaline phosphatase substrate kit (Vector, SK-5100).608 Cell Stem Cell 10, 595–609, May 4, 2012 ª2012 Elsevier Inc.RNA FISH and qPCR
RNA FISH was carried out as previously described (Erwin and Lee, 2010). In
brief, cellswere trypsinized, spunonto slides (cytospin),washed inPBS, placed
in cytoskeletal buffer containing 0.5% Triton X, and then fixed in 4% parafor-
maldehyde. DNA probes were generated to the first 5 kb of human XIST exon
1, labeled with fluorescein-12-dUTP using the Prime-It Fluor Labeling kit (Stra-
tagene). Hybridizations were carried out in buffer containing human Cot1 DNA
(Invitrogen) at 37C overnight. After washes, slides were mounted with Vecta-
shield (Vector Labs) containing DAPI and imaged. For immunostaining, slides
were blocked in 10% FBS and then stained as described above. 500–1000
nuclei were scored for each line forXIST andH3K27me3 assays. For RNAanal-
ysis, total RNA was isolated from cultures using Trizol (Invitrogen) and synthe-
sized into cDNA with iScript (Bio-Rad). qRT-PCR was then performed using
SYBR green (Bio-Rad) and the iCycler system (Bio-Rad). Quantitative levels
for all genes were normalized to endogenous GAPDH expression.Teratoma Assay
hiPSCs were trypsinized and injected into the kidney of SCID mice (SHO).
Tissuemasses were formed within 8–10 weeks. Masses were extracted, fixed,
sectioned, and stained. Cells representing all three germ layers were identified
under the microscope.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
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